Skip to main content

Table 2 Predictors of saline-induced bronchoconstriction

From: Loss of bronchoprotection to Salbutamol during sputum induction with hypertonic saline: implications for asthma therapy

 

All patients, n = 3565

No.

FEV1 fall > 15%, no. (%)

OR (95% CI)

p value

High ICS dose

785

84 (10.7)

1.85 (1.11–3.09)

0.019

LABA use

2426

142 (10.0)

2.02 (1.32–3.10)

0.001

FEV1 < 60% predicted

596

93 (15.6)

3.29 (2.06–5.26)

< 0.001

FEV1/VC < 70%

1165

149 (12.8)

2.08 (1.40–3.10)

< 0.001

  1. ICS inhaled corticosteroid, LABA long-acting β-agonist
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us